Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Rejects Pfizer's Xeljanz In Plaque Psoriasis

This article was originally published in Scrip

Executive Summary

After the markets closed on Oct. 14, Pfizer Inc. disclosed the FDA had rejected the firm's supplemental new drug application (sNDA) for its JAK inhibitor Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe chronic plaque psoriasis.



Related Companies